Publications by authors named "A Lavagna"
Article Synopsis
- The study investigates how the combination of amyloid beta and tau pathologies affects neurodegeneration in Alzheimer's disease using a new transgenic rat model (McGill-R-APPxhTau).
- Initial findings suggest that early exposure to both amyloid and phosphorylated tau can temporarily improve synaptic plasticity and cognitive functions, contrasting with the negative effects observed in models with only one of these pathologies.
- However, as the disease progresses, the combined presence of amyloid and tau leads to severe cognitive decline, increased neuroinflammation, and neuronal loss, indicating that the protective effects of tau are short-lived.
The application of the selective allosteric M1 muscarinic and sigma-1 receptor agonist, AF710B (aka ANAVEX3-71), has shown to attenuate Alzheimer's disease-like hallmarks in McGill-R-Thy1-APP transgenic rats when administered at advanced pathological stages. It remains unknown whether preventive treatment strategies applying this compound may be equally effective. We tested whether daily oral administration of AF710B (10 µg/kg) in 7-month-old, preplaque, McGill-R-Thy1-APP rats for 7 months, followed by a 4-week washout period, could prevent Alzheimer's disease-like pathological hallmarks.
View Article and Find Full Text PDFBackground And Aims: Telemonitoring is increasingly used in the management of IBD patients. We investigated the agreement between patients and physicians on scores of disease activity and burden.
Methods: Consecutive outpatients at one IBD clinic were recruited between February and December 2021.
Article Synopsis
- Adalimumab is a treatment for ulcerative colitis, but more data on its effectiveness and safety are needed, prompting a study of 381 adult patients across 19 hospitals.
- The study found that at 12 months, 33.6% of patients achieved remission and 44 patients required colectomy, with factors like steroid use and severe disease at baseline influencing treatment outcomes.
- Overall, the findings suggest that adalimumab is both safe and effective for managing ulcerative colitis, with significant clinical responses observed within the first 8 weeks of treatment.*
COVID-19 has dramatically impacted endoscopy practice because upper endoscopy procedures can be aerosol-generating. Most elective procedures have been rescheduled. Endoscopic retrograde cholangiopancreatography (ERCP) is frequently performed in emergency or urgent settings in which rescheduling is not possible.
View Article and Find Full Text PDF